CHICAGO—The consequences of diminishing federal support for cancer research can be measured in the abstracts presented at the 50th annual meeting of the American Society of Clinical Oncology that concluded earlier this week.
The budgets of operations and statistical centers of adult clinical trials groups were cut by about $20.4 million, group chairs say.
NCI officials said they plan to hold a series of meetings with clinical trials group chairs and group financial officers in order to fine-tune the new National Clinical Trials Network.
Almost one decade ago, Laurie Fenton-Ambrose, president and CEO of the Lung Cancer Alliance, described the National Lung Screening Trial as “failed” and “outdated.”
